Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B). - Stemler J; Yeghiazaryan L; Stephan C; Mohn KG; Carcas-Sansuan AJ; Rodriguez ER; Moltó J; Mitxeltorena IV; Welte T; Zablockienė B; Akova M; Bethe U; et al. (International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2024)